{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T08:29:09Z","timestamp":1774686549636,"version":"3.50.1"},"reference-count":138,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,5,15]]},"DOI":"10.1097\/01.tp.0000262706.28513.6a","type":"journal-article","created":{"date-parts":[[2007,5,10]],"date-time":"2007-05-10T08:13:37Z","timestamp":1178784817000},"page":"1141-1150","source":"Crossref","is-referenced-by-count":65,"title":["Reducing the Risks of Cardiovascular Disease in Liver Allograft Recipients"],"prefix":"10.1097","volume":"83","author":[{"given":"George","family":"Mells","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Neuberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-1-20210129","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1440-1746.1993.tb01654.x","article-title":"A follow up of 53 patients alive beyond two years following liver transplantation.","volume":"8","author":"McCaughan","year":"1993","journal-title":"J Gastroenterol Hepatol"},{"key":"R2-1-20210129","first-page":"1057","article-title":"Metabolic complications after liver transplantation. Diabetes, hypercholesterolaemia, hypertension, and obesity.","volume":"60","author":"Stegall","year":"1995","journal-title":"Transplantation"},{"key":"R3-1-20210129","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1399-0012.1997.tb00782.x","article-title":"Cardiovascular risk factors in long-term follow up after orthotopic liver transplantation.","volume":"11","author":"Guckelberger","year":"1997","journal-title":"Clin Transplant"},{"key":"R4-1-20210129","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1097\/00007890-200003150-00018","article-title":"Long-term medical complications in patients surviving >=5 years after liver transplant.","volume":"69","author":"Sheiner","year":"2000","journal-title":"Transplantation"},{"key":"R5-1-20210129","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1111\/j.1432-2277.2002.tb00107.x","article-title":"Cardiovascular risk factors in 116 patients 5 years or more after liver transplantation.","volume":"15","author":"Fernandez-Miranda","year":"2002","journal-title":"Transpl Int"},{"key":"R6-1-20210129","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1097\/00007890-200203270-00012","article-title":"Cardiovascular morbidity and mortality after orthotopic liver transplantation.","volume":"27","author":"Johnston","year":"2002","journal-title":"Transplantation"},{"key":"R7-1-20210129","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/01.TP.0000100685.70064.90","article-title":"Is there disparity between risk and incidence of cardiovascular disease after liver transplant?","volume":"77","author":"Neal","year":"2004","journal-title":"Transplantation"},{"key":"R8-1-20210129","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/j.1432-2277.2005.00174.x","article-title":"Coronary event rates in liver transplant recipients reflect the increased prevalence of cardiovascular risk-factors.","volume":"18","author":"Guckelberger","year":"2005","journal-title":"Transpl Int"},{"key":"R9-1-20210129","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0041-1345(03)00640-7","article-title":"Cardiovascular morbidity and obesity in adult liver transplant recipients.","volume":"35","author":"Mazuelos","year":"2003","journal-title":"Transplant Proc"},{"key":"R10-1-20210129","first-page":"323","article-title":"Long-term medical complications and quality of life in adult recipients surviving 10 years or more after liver transplantation.","volume":"68","author":"Ciccarelli","year":"2005","journal-title":"Acta Gastroenterol Belg"},{"key":"R11-1-20210129","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1053\/jlts.2001.27084","article-title":"Analysis of causes of death in liver transplant recipients who survived more than 3 years.","volume":"7","author":"Pruthi","year":"2001","journal-title":"Liver Transpl"},{"key":"R12-1-20210129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1291\/hypres.19.1","article-title":"Mechanism of glucocorticoid-induced hypertension.","volume":"19","author":"Saruta","year":"1996","journal-title":"Hypertens Res"},{"key":"R13-1-20210129","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1177\/1099800402004001003","article-title":"Impaired vasodilatation and nitric oxide synthase activity in glucocorticoid-induced hypertension.","volume":"4","author":"Mitchell","year":"2002","journal-title":"Biol Res Nurs"},{"key":"R14-1-20210129","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1161\/01.HYP.18.4.458","article-title":"Cyclosporine causes sympathetically mediated elevations in arterial pressure in rats.","volume":"18","author":"Morgan","year":"1991","journal-title":"Hypertension"},{"key":"R15-1-20210129","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM199009133231101","article-title":"Cyclosporine-induced sympathetic activation and hypertension after heart transplantation.","volume":"323","author":"Scherrer","year":"1990","journal-title":"NEJM"},{"key":"R16-1-20210129","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/ki.1988.92","article-title":"Cyclosporine A enhances renin secretion and production in isolated juxtaglomerular cells.","volume":"33","author":"Kurtz","year":"1988","journal-title":"Kidney Int"},{"key":"R17-1-20210129","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1161\/01.HYP.0000085195.38870.44","article-title":"Role of angiotensin II and reactive oxygen species in cyclosporine A dependent-hypertension.","volume":"42","author":"Nishiyama","year":"2003","journal-title":"Hypertension"},{"key":"R18-1-20210129","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1046\/j.1523-1755.1999.00481.x","article-title":"Cyclosporine A up-regulates angiotensin II receptors and calcium responses in human vascular smooth muscle cells.","volume":"55","author":"Avdonin","year":"1999","journal-title":"Kidney Int"},{"key":"R19-1-20210129","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1161\/01.HYP.0000068201.48340.3B","article-title":"Cyclosporin A disrupts bradykinin signalling through superoxide.","volume":"41","author":"Vetter","year":"2003","journal-title":"Hypertension"},{"key":"R20-1-20210129","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1681\/ASN.V5111910","article-title":"Renal sodium handling with cyclosporine A and FK506 after orthotopic liver transplantation.","volume":"5","author":"Canzanello","year":"1995","journal-title":"J Am Soc Nephrol"},{"key":"R21-1-20210129","first-page":"1983","article-title":"World Health Organisation-International Society of Hypertension guidelines for the management of hypertension.","volume":"21","author":"Whitworth","year":"2003","journal-title":"J Hypertens"},{"key":"R22-1-20210129","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1097\/00004872-200306000-00001","article-title":"2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension.","volume":"21","year":"2003","journal-title":"J Hypertens"},{"key":"R23-1-20210129","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/sj.jhh.1001683","article-title":"Guidelines for management of hypertension: Report of the fourth working party of the British Hypertension Society, 2004- BHS IV.","volume":"18","author":"Williams","year":"2004","journal-title":"J Human Hypertens"},{"key":"R24-1-20210129","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","article-title":"The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure- The JNC-7 Report.","volume":"289","author":"Chobanian","year":"2003","journal-title":"JAMA"},{"key":"R25-1-20210129","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","article-title":"Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: Principle results of the Hypertension Optimal Treatment (HOT) randomised trial.","volume":"351","author":"Hansson","year":"1998","journal-title":"Lancet"},{"key":"R26-1-20210129","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJM199403313301301","article-title":"The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease.","volume":"330","author":"Klahr","year":"1994","journal-title":"N Engl J Med"},{"key":"R27-1-20210129","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1399-0012.2004.00315.x","article-title":"Hypertension, antihypertensive agents and outcomes following renal transplantation.","volume":"19","author":"Tutone","year":"2005","journal-title":"Clin Transplant"},{"key":"R28-1-20210129","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.1053\/ajkd.1998.v32.pm9820471","article-title":"Hypertension in patients with chronic renal disease.","volume":"32","author":"Mailloux","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"R29-1-20210129","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1161\/01.HYP.0000037217.96002.8E","article-title":"Results of the diet, exercise, and weight loss intervention trial (DEW-IT).","volume":"40","author":"Miller","year":"2002","journal-title":"Hypertension"},{"key":"R30-1-20210129","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1161\/01.HYP.0000091267.39066.72","article-title":"Individual blood pressure responses to changes in salt intake: Results from the DASH-sodium trial.","volume":"42","author":"Obarzanek","year":"2003","journal-title":"Hypertension"},{"key":"R31-1-20210129","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1161\/01.HYP.34.3.472","article-title":"Effect of dietary patterns on ambulatory blood pressure. Results from the Dietary Approaches to Stop Hypertension (DASH) Trial.","volume":"34","author":"Moore","year":"1999","journal-title":"Hypertension"},{"key":"R32-1-20210129","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1161\/hy1101.093424","article-title":"Effects of alcohol reduction on blood pressure:a meta-analyis of randomised controlled trials.","volume":"38","author":"Xin Xue","year":"2001","journal-title":"Hypertension"},{"key":"R33-1-20210129","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.transproceed.2006.02.103","article-title":"The impact of daily sodium intake on post-transplant hypertension in kidney allograft recipients.","volume":"38","author":"Keven","year":"2006","journal-title":"Transplant Proc"},{"key":"R34-1-20210129","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1399-0012.2005.00437.x","article-title":"The role of dietary cations in the blood pressure of renal transplant recipients.","volume":"20","author":"Ramesh Prasad","year":"2006","journal-title":"Cin Transplant"},{"key":"R35-1-20210129","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/j.transproceed.2005.04.002","article-title":"Role of dietary salt intake in post-transplant hypertension with tacrolimus-based immunosuppression.","volume":"37","author":"Prasad","year":"2005","journal-title":"Transplant Proc"},{"key":"R36-1-20210129","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1399-0012.1996.tb00467.x","article-title":"Gastric bypass in morbidly obese kidney transplant recipients.","volume":"10","author":"Marterre","year":"1996","journal-title":"Clin Transplant"},{"key":"R37-1-20210129","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S0140-6736(03)14739-3","article-title":"Effects of different blood-pressure-lowering regimens on major cardiovascular events: Results of prospectively-designed overviews of randomised trials.","volume":"362","year":"2003","journal-title":"Lancet"},{"key":"R38-1-20210129","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(05)67573-3","article-title":"Should beta-blockers remain first choice in the treatment of primary hypertension? A meta-analysis.","volume":"366","author":"Lindholm","year":"2005","journal-title":"Lancet"},{"key":"R39-1-20210129","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0895-7061(99)00171-5","article-title":"Hypertension after liver transplantation: A predictive role for pre-treatment hemodynamics and effects of isradipine on the systemic and renal circulations.","volume":"13","author":"Taler","year":"2000","journal-title":"Am J Hypertens"},{"key":"R40-1-20210129","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1161\/01.HYP.23.1_Suppl.I220","article-title":"Systemic and renal effects of nifedipine in cyclosporine-associated hypertension.","volume":"23","author":"Textor","year":"1994","journal-title":"Hypertension"},{"key":"R41-1-20210129","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.transproceed.2005.01.066","article-title":"Comparison between nifedipine and carvedilol in the treatment of de novo arterial hypertension after liver transplantation: Preliminary results of a controlled clinical trial.","volume":"37","author":"Galioto","year":"2005","journal-title":"Transplant Proc"},{"key":"R42-1-20210129","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1097\/01.TP.0000116418.78963.DC","article-title":"Hemodynamic effects of amlodipine, bisoprolol, and lisinopril in hypertensive patients after liver transplantation.","volume":"77","author":"Neal","year":"2004","journal-title":"Transplantation"},{"key":"R43-1-20210129","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/oxfordjournals.ndt.a027840","article-title":"Renal and systemic effects of atenolol and tertatolol in renal transplant recipients on cyclosporine A.","volume":"13","author":"Branten","year":"1998","journal-title":"Nephrol Dial Transplant"},{"key":"R44-1-20210129","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1093\/ndt\/13.9.2327","article-title":"The effect of felodipine on renal function and blood pressure in cyclosporine-treated renal transplant patients during the first three months after transplantation.","volume":"13","author":"Madsen","year":"1998","journal-title":"Nephrol Dial Transplant"},{"key":"R45-1-20210129","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1093\/ndt\/13.10.2612","article-title":"Renal and haemodynamic effects of amlodipine and nifedipine in hypertensive renal transplant recipients.","volume":"13","author":"Venkat-Raman","year":"1998","journal-title":"Nephrol Dial Transplant"},{"key":"R46-1-20210129","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1161\/01.HYP.26.3.436","article-title":"Comparison of perindopril and amlodipine in cyclosporine-treated renal allograft recipients.","volume":"26","author":"Sennesael","year":"1995","journal-title":"Hypertension"},{"key":"R47-1-20210129","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/ki.1993.61","article-title":"Converting-enzyme inhibitor versus calcium antagonist in cyclosporine-treated renal transplants.","volume":"43","author":"Mourad","year":"1993","journal-title":"Kidney Int"},{"key":"R48-1-20210129","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1161\/01.HYP.33.3.862","article-title":"ACE-inhibitor versus beta-blocker for the treatment of hypertension in renal allograft recipients.","volume":"33","author":"Hausberg","year":"1999","journal-title":"Hypertension"},{"key":"R49-1-20210129","doi-asserted-by":"crossref","first-page":"S135","DOI":"10.1046\/j.1523-1755.1998.06827.x","article-title":"Efficacy and safety of losartan in the treatment of hypertension in renal transplant recipients.","volume":"68","author":"Del Castillo","year":"1998","journal-title":"Kidney Int Suppl"},{"key":"R50-1-20210129","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1093\/ndt\/15.1.82","article-title":"Long-term antiproteiuric effect of losartan in renal transplant recipients treated for hypertension.","volume":"15","author":"Calvino","year":"2000","journal-title":"Nephrol Dial Transplant"},{"key":"R51-1-20210129","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/S0041-1345(03)00631-6","article-title":"Efficacy and safety of doxazosin GITS in hypertensive renal transplant patients: Comparison of 8 and 4mg.","volume":"35","author":"Oliveras","year":"2003","journal-title":"Transplant Proc"},{"key":"R52-1-20210129","doi-asserted-by":"crossref","first-page":"S130","DOI":"10.1046\/j.1523-1755.1998.06826.x","article-title":"Treatment of hypertension after renal transplantation: Long-term efficacy of verapamil, enalapril, and doxazosin.","volume":"68","author":"Martinez-Castelao","year":"1998","journal-title":"Kidney Int Suppl"},{"key":"R53-1-20210129","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/00007890-199608150-00011","article-title":"Progressive histologic injury in kidneys from heart and liver transplant recipients receiving cyclosporine.","volume":"62","author":"Falkenheim","year":"1996","journal-title":"Transplantation"},{"key":"R54-1-20210129","first-page":"69","article-title":"Effect of felodipine on renal haemodynamics and tubular sodium handling in cyclosporine-treated renal transplant receipients.","volume":"7","author":"Sorensen","year":"1992","journal-title":"Nephrol Dial Transplant"},{"key":"R55-1-20210129","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3109\/00365519509110262","article-title":"Effect of felodipine on renal haemodynamics and tubular sodium handling after single-dose cyclosporine infusion in renal transplant recipients treated with azathioprine and prednisolone.","volume":"55","author":"Madsen","year":"1995","journal-title":"Scand J Clin Lab Invest"},{"key":"R56-1-20210129","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/ki.1993.101","article-title":"Calcium channel blockers protect transplant patients from cyclosporine-induced daily renal hypoperfusion.","volume":"43","author":"Ruggenenti","year":"1993","journal-title":"Kidney Int"},{"key":"R57-1-20210129","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1093\/ndt\/12.3.480","article-title":"Effects of the calcium antagonist felodipine on renal haemodynamics, tubular sodium handling, and blood pressure in cyclosporine-treated dermatological patients.","volume":"12","author":"Madsen","year":"1997","journal-title":"Nephrol Dial Transplant"},{"key":"R58-1-20210129","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1097\/01.TP.0000137793.23371.42","article-title":"Calcium channel blockade and preservation of renal graft function in cyclosporine-treated recipients: A prospective randomized placebo-controlled 2-year study.","volume":"78","author":"Kuypers","year":"2004","journal-title":"Transplantation"},{"key":"R59-1-20210129","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/S0140-6736(99)08421-4","article-title":"Effects of nitrendipine on renal function in renal-transplant patients treated with cyclosporine: A randomised trial.","volume":"354","author":"Rahn","year":"1999","journal-title":"Lancet"},{"key":"R60-1-20210129","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1034\/j.1399-0012.2000.140313.x","article-title":"The beneficial effects of calcium channel blockers on long-term kidney transplant survival are independent of blood pressure reduction.","volume":"14","author":"Mehrens","year":"2000","journal-title":"Clin Transplant"},{"key":"R61-1-20210129","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0149-2918(96)80030-0","article-title":"Effect of nifedipine on renal function in liver transplant recipients receiving tacrolimus.","volume":"18","author":"Seifeldin","year":"1996","journal-title":"Clint Ther"},{"key":"R62-1-20210129","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/ajh\/5.7.423","article-title":"Effect of enalapril on the progression of chronic renal failure.","volume":"5","author":"Kamper","year":"1992","journal-title":"AM J Hypertens"},{"key":"R63-1-20210129","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/ki.1996.165","article-title":"Role of transforming growth factor-beta 1 in experimental chronic cyclosporine nephropathy.","volume":"49","author":"Shihab","year":"1996","journal-title":"Kidney Int"},{"key":"R64-1-20210129","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1097\/00007890-199712270-00034","article-title":"Mechanism of fibrosis in experimental tacrolimus nephrotoxicity.","volume":"64","author":"Shihab","year":"1997","journal-title":"Transplantation"},{"key":"R65-1-20210129","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1681\/ASN.V124822","article-title":"Effects of losartan and amlodipine on intrarenal haemodynamics and TGF-beta plasma levels in a crossover trial in renal transplant recipients.","volume":"12","author":"Inigo","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"R66-1-20210129","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/ki.1997.380","article-title":"Angiotensin II blockade decreases TGF-beta1 and matrix proteins in cyclosporine nephropathy.","volume":"52","author":"Shibab","year":"1997","journal-title":"Kidney Int"},{"key":"R67-1-20210129","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1016\/j.transproceed.2004.10.013","article-title":"Friedman AL, Lorber MI, Bia MJ. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers used for the treatment of hypertension appear to be safe in the early post-transplant period.","volume":"36","author":"Formica","year":"2004","journal-title":"Transplant Proc"},{"key":"R68-1-20210129","first-page":"S97","article-title":"Renal haemodynamics in hypertensive renal allograft recipients: Effects of calcium antagonists and ACE inhibitors.","volume":"55","author":"Grekas","year":"1996","journal-title":"Kidney Int Supp"},{"key":"R69-1-20210129","first-page":"299","article-title":"Management of moderate to severe hypertension and proteinuria by nifedipine retard and perindopril after renal transplantation.","volume":"44","author":"Grekas","year":"1995","journal-title":"Clin Nephrol"},{"key":"R70-1-20210129","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1432-2277.2003.tb00306.x","article-title":"Long-term follow up of ACE-inhibitor versus beta-blocker treatment and their effects on blood pressure and kidney function in renal transplant recipients.","volume":"16","author":"Suwelack","year":"2003","journal-title":"Transpl Int"},{"key":"R71-1-20210129","doi-asserted-by":"crossref","first-page":"c84","DOI":"10.1159\/000074321","article-title":"Renoprotective effects of losartan in renal transplant recipients. Results of retrospective study.","volume":"95","author":"Inigo","year":"2003","journal-title":"Nephron Clin Pract"},{"key":"R72-1-20210129","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1097\/00007890-200112150-00013","article-title":"Sustained improvement of renal graft function for two years in hypertensive renal transplant recipients treated with nifedipine as compared to lisinopril.","volume":"72","author":"Midtvedt","year":"2001","journal-title":"Transplantation"},{"key":"R73-1-20210129","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/sj.jhh.1001767","article-title":"Blood pressure control in kidney transplantation: Therapeutic implications.","volume":"18","author":"Premasathian","year":"2004","journal-title":"J Hum Hypertens"},{"key":"R74-1-20210129","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/sj.jhh.1001766","article-title":"Hypertension after renal transplantation.","volume":"18","author":"Textor","year":"2004","journal-title":"J Hum Hypertension"},{"key":"R75-1-20210129","first-page":"S25","article-title":"European best practice guidelines for renal transplantation. Section IV. Long-term management of the transplant recipient. IV. 52 Cardiovascular risks Arterial hypertension.","volume":"17","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"R76-1-20210129","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S0039-6060(05)80050-9","article-title":"Corticosteroid withdrawal after liver transplantation.","volume":"118","author":"Punch","year":"1995","journal-title":"Surgery"},{"key":"R77-1-20210129","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/hep.510250132","article-title":"Prednisolone withdrawal late after adult liver transplantation reduces diabetes, hypertension, and hypercholesterolaemia without causing graft loss.","volume":"25","author":"Stegall","year":"1997","journal-title":"Hepatology"},{"key":"R78-1-20210129","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/lt.500040404","article-title":"Late hypertension after liver transplantation: A comparison of cyclosporine and tacrolimus (FK 506).","volume":"4","author":"Canzanello","year":"1998","journal-title":"Liver Transpl Surg"},{"key":"R79-1-20210129","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1111\/j.1432-2277.1994.tb01304.x","article-title":"Renal complications and development of hypertension in the European study of FK506 and cyclosporine in primary liver transplant recipients.","volume":"7","author":"Devlin","year":"1994","journal-title":"Transpl Int"},{"key":"R80-1-20210129","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/j.1600-6143.2005.00808.x","article-title":"A comparison of tacrolimus and cyclosporine in liver transplantation: Effects on renal function and cardiovascular risk status.","volume":"5","author":"Lucey","year":"2005","journal-title":"Am J Transplant"},{"key":"R81-1-20210129","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1053\/jlts.2001.24637","article-title":"Beneficial effects of converting liver transplant recipients from cyclosporine to tacrolimus on blood pressure, serum lipids, and weight.","volume":"7","author":"Neal","year":"2001","journal-title":"Liver Transpl"},{"key":"R82-1-20210129","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/hep.510240518","article-title":"Cyclosporin A: Drug discontinuation for the management of long-term toxicity after liver transplantation.","volume":"24","author":"Chan","year":"1996","journal-title":"Hepatology"},{"key":"R83-1-20210129","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/hep.1840190419","article-title":"Cyclosporine withdrawal for nephrotoxicity in liver transplant recipients does not result in sustained improvement in renal function and causes cellular and ductopenic rejection.","volume":"19","author":"Sandborn","year":"1994","journal-title":"Hepatology"},{"key":"R84-1-20210129","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/lt.500050513","article-title":"Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil.","volume":"5","author":"Herrero","year":"1999","journal-title":"Liver Transpl Surg"},{"key":"R85-1-20210129","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1016\/S0041-1345(03)00643-2","article-title":"Effectiveness and safety of mycophenolate mofetil as monotherapy in liver transplantation.","volume":"35","author":"Moreno","year":"2003","journal-title":"Transplant Proc"},{"key":"R86-1-20210129","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S0140-6736(00)04055-1","article-title":"Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study.","volume":"357","author":"Schlitt","year":"2001","journal-title":"Lancet"},{"key":"R87-1-20210129","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1097\/01.ASN.0000113248.59077.76","article-title":"Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal.","volume":"15","author":"Kreis","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"R88-1-20210129","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1034\/j.1600-6143.2003.00010.x","article-title":"Diabetes mellitus after kidney transplantation in the United States.","volume":"3","author":"Kasiske","year":"2003","journal-title":"Am J Transplant"},{"key":"R89-1-20210129","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1097\/00007890-199710150-00008","article-title":"Glucose intolerance after renal transplantation depends on prednisolone dose and recipient age.","volume":"64","author":"Hjelmesaeth","year":"1997","journal-title":"Transplantation"},{"key":"R90-1-20210129","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1046\/j.1600-6143.2003.00372.x","article-title":"New onset diabetes mellitus in patients receiving Calcineurin inihibitors: A systemic review and meta-analysis.","volume":"4","author":"Heisel","year":"2004","journal-title":"Am J Transplant"},{"key":"R91-1-20210129","doi-asserted-by":"crossref","first-page":"SS3","DOI":"10.1097\/01.TP.0000069952.49242.3E","article-title":"New onset diabetes after transplantation: 2003 International Consensus Guidelines.","volume":"75","author":"Davidson","year":"2003","journal-title":"Transplantation"},{"key":"R92-1-20210129","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.2337\/diacare.26.2007.S5","article-title":"Report of the expert committee on the diagnosis and classification of diabetes mellitus.","volume":"26","year":"2003","journal-title":"Diabetes Care"},{"key":"R93-1-20210129","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared to conventional treatment and risk of complications in patients with type 2 diabetes mellitus (UKPDS 33).","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"R94-1-20210129","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"key":"R95-1-20210129","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/pdi.887","article-title":"New-onset diabetes after transplantation.","volume":"23","author":"Krentz","year":"2006","journal-title":"Pract Diab Int"},{"key":"R96-1-20210129","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1111\/j.1600-6143.2004.00613.x","article-title":"Pioglitazone in the management of diabetes mellitus after transplantation.","volume":"4","author":"Luther","year":"2004","journal-title":"Am J Transplant"},{"key":"R97-1-20210129","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1097\/01.tp.0000181165.19788.95","article-title":"Rosiglitazone therapy of posttransplant diabetes mellitus.","volume":"80","author":"Villanueva","year":"2005","journal-title":"Transplantation"},{"key":"R98-1-20210129","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1432-2277.2000.tb01040.x","article-title":"Treatment of tacrolimus-related adverse effects by conversion to cyclosporine in liver transplant recipients.","volume":"13","author":"Emre","year":"2000","journal-title":"Transpl Int"},{"key":"R100-1-20210129","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"R101-1-20210129","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1016\/S0140-6736(03)13638-0","article-title":"for the Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators. Effect of fluvasatatin on cardiac outcomes in renal transplant recipients: A multicentre, randomised, placebo-controlled trial.","volume":"361","author":"Holdaas","year":"2003","journal-title":"Lancet"},{"key":"R102-1-20210129","first-page":"S3","article-title":"Clinical practice guidelines for managing dyslipidaemias in kidney transplant patients: A report for the managing dyslipidaemias in chronic kidney disease work group of the national kidney foundation kidney diseases outcome quality initiative.","volume":"4","author":"Kasike","year":"2004","journal-title":"Am J Transplant"},{"key":"R103-1-20210129","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1136\/gut.51.2.265","article-title":"Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis.","volume":"51","author":"Longo","year":"2002","journal-title":"Gut"},{"key":"R104-1-20210129","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/00007890-199001000-00013","article-title":"The effects of the American Heart Association step 1 diet on hyperlipidaemia following renal transplantation.","volume":"49","author":"Moore","year":"1990","journal-title":"Transplantation"},{"key":"R105-1-20210129","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/0735-1097(92)90340-S","article-title":"Hyperlipidaemia after heart transplantation: Report of a 6-year experience with treatment recommendations.","volume":"19","author":"Ballantyne","year":"1992","journal-title":"J Am Coll Cardiol"},{"key":"R107-1-20210129","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins.","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"R108-1-20210129","first-page":"141","article-title":"Effects of pravastatin for hypercholesterolaemia in cardiac transplant recipients.","volume":"21","author":"Kobashigawa","year":"1993","journal-title":"J Am Coll Cardiol"},{"key":"R109-1-20210129","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/0002-9149(89)90492-X","article-title":"Lovastatin therapy for hypercholesterolaemia in cardiac transplant recipients.","volume":"64","author":"Kuo","year":"1989","journal-title":"Am J Cardiol"},{"key":"R110-1-20210129","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/00007890-199407000-00008","article-title":"Low-dose simvastatin for the treatment of hyperlipidaemia in recipients of cardiac transplant recipients treated with cyclosporine.","volume":"58","author":"Barbir","year":"1994","journal-title":"Transplantation"},{"key":"R111-1-20210129","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/00007890-199001000-00021","article-title":"Lovastatin treatment of hypercholesterolaemia in renal transplant recipients.","volume":"49","author":"Kasiske","year":"1990","journal-title":"Transplantation"},{"key":"R112-1-20210129","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/00007890-199201000-00018","article-title":"The effects of pravastatin on hyperlipidaemia in renal transplant recipients.","volume":"53","author":"Yoshimura","year":"1992","journal-title":"Transplantation"},{"key":"R113-1-20210129","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0002-9149(05)80029-3","article-title":"A preliminary report of the safety and efficacy of fluvastatin for hypercholesterolaemia in renal transplant patients receiving cyclosporine.","volume":"76","author":"Goldberg","year":"1995","journal-title":"Am J Cardiol"},{"key":"R114-1-20210129","first-page":"934","article-title":"Hyperlipidaemia after liver transplantation: Natural history and treatment with the hydroxyl-methylglutaryl-coenzyme A reductase inhibitor pravastatin.","volume":"62","author":"Imigawa","year":"1996","journal-title":"Transplantation"},{"key":"R115-1-20210129","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1345\/aph.1D388","article-title":"Effect of atorvastatin on cyclosporine pharmacokinetics in liver transplant recipients.","volume":"38","author":"Taylor","year":"2004","journal-title":"Ann Pharmacother"},{"key":"R116-1-20210129","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1159\/000013487","article-title":"Effects of simvastatin and pravastatin on hyperlipidaemia and cyclosporin blood levels in renal transplant recipients.","volume":"19","author":"Capone","year":"1999","journal-title":"Am J Nephrol"},{"key":"R117-1-20210129","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1034\/j.1600-6143.2001.10415.x","article-title":"Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipiemts.","volume":"1","author":"Asberg","year":"2001","journal-title":"Am J Transpl"},{"key":"R118-1-20210129","first-page":"84","article-title":"Cyclosporine and pravastatin pharmacokinetics in cardiac transplant recipients.","volume":"16","author":"Kobashigawa","year":"1997","journal-title":"J Heart Lung Transplant"},{"key":"R119-1-20210129","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1345\/aph.10228","article-title":"Rhabdomyolysis and HMG-CoA reductase inhibitors.","volume":"35","author":"Omar","year":"2001","journal-title":"Ann Pharmacother"},{"key":"R120-1-20210129","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/00007890-199702150-00001","article-title":"Hyperlipidaema in solid organ transplantation.","volume":"63","author":"Kobashigawa","year":"1997","journal-title":"Transplantation"},{"key":"R121-1-20210129","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1111\/j.1600-6143.2005.01005.x","article-title":"Combined therapy with atorvastatin and calcineurin inhibitors: No interaction with tacrolimus.","volume":"5","author":"Lemahieu","year":"2005","journal-title":"Am J Transplant"},{"key":"R122-1-20210129","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0021-9150(01)00438-5","article-title":"Changes in lipid metabolism and effects of simvastatin in renal transplant recipients induced by cyclosporine or tavrolimus.","volume":"158","author":"Ichimaru","year":"2001","journal-title":"Atherosclerosis"},{"key":"R123-1-20210129","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1600-6143.2005.01132.x","article-title":"Ezetimibe for the treatment of uncontrolled hypercholesterolaemia in patients with high dose statin therapy after renal transplantation.","volume":"6","author":"Kohnle","year":"2006","journal-title":"Am J Transpl"},{"key":"R124-1-20210129","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1097\/01.tp.0000203167.77570.11","article-title":"Ezetimibe in renal transplant patients with hyperlipidaemia resistant to HMG-CoA reductase inhibitors.","volume":"81","author":"Langone","year":"2006","journal-title":"Transplantation"},{"key":"R125-1-20210129","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/j.1600-6143.2006.01263.x","article-title":"A retrospective analysis of ezetimibe treatment in renal transplant recipients.","volume":"6","author":"Buchanan","year":"2006","journal-title":"Am J Transplant"},{"key":"R126-1-20210129","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.transproceed.2004.12.231","article-title":"Treatment of hypercholesterolemia with ezetimibe in the kidney transplant population.","volume":"37","author":"Puthenparumpil","year":"2005","journal-title":"Transplant Proc"},{"key":"R127-1-20210129","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1345\/aph.1G015","article-title":"Supratherapeutic response to ezetimibe administered with cyclosporine.","volume":"39","author":"Koshman","year":"2005","journal-title":"Ann Pharmacother"},{"key":"R128-1-20210129","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1159\/000187986","article-title":"Hyperlipidemia after renal transplantation: Treatment with gemfibrozil.","volume":"67","author":"Chan","year":"1994","journal-title":"Nephron"},{"key":"R129-1-20210129","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/j.1399-0012.1995.tb00347.x","article-title":"Post-transplant hyperlipidaemia: Risk factors and response to dietary modification and gemfibrozil therapy.","volume":"9","author":"Bastani","year":"1995","journal-title":"Clin Transplant"},{"key":"R130-1-20210129","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/00045391-199702000-00006","article-title":"A crossover comparison of the efficacy and safety of lovastatin and gemfibrozil in the treatment of hyperlipidemic organ transplant recipients.","volume":"4","author":"Hanes","year":"1997","journal-title":"Am J Ther"},{"key":"R131-1-20210129","first-page":"613","article-title":"Cholesterol-lowering therapy after heart transplantation: A 12-month randomized trial.","volume":"14","author":"Pflugfelder","year":"1995","journal-title":"J Heart Lung Transplant"},{"key":"R132-1-20210129","first-page":"461","article-title":"Lovastatin versus bezafibrate for hyperlipemia treatment after heart transplantation.","volume":"14","author":"Hidalgo","year":"1995","journal-title":"J Heart Lung Transplant"},{"key":"R133-1-20210129","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1159\/000013337","article-title":"Lack of effect of gemfibrozil on cyclosporine blood concentrations in kidney-transplanted patients.","volume":"18","author":"Pisanti","year":"1998","journal-title":"Am J Nephrol"},{"key":"R134-1-20210129","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/BF01740664","article-title":"Pharmacokinetics of cyclosporine in hyperlipidaemic long-term survivors of heart transplantation. Lack of interaction with the lipid-lowering agent, fenofibrate.","volume":"43","author":"deLorgeril","year":"1992","journal-title":"Eur J Clin Pharmacol"},{"key":"R135-1-20210129","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/00007890-199407270-00018","article-title":"The long-term effects of the lipid-lowering agent fenofibrate in hyperlipidemic heart transplant recipients.","volume":"58","author":"Boissonnat","year":"1994","journal-title":"Transplantation"},{"key":"R136-1-20210129","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1177\/00912700022008874","article-title":"Lack of a clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteers.","volume":"40","author":"Pan","year":"2000","journal-title":"J Clin Pharmacol"},{"key":"R137-1-20210129","doi-asserted-by":"crossref","first-page":"80A","DOI":"10.1016\/S0002-9149(05)80024-4","article-title":"Pharmacokinetics of the combination of fluvastatin and gemfibrozil.","volume":"76","author":"Spence","year":"1995","journal-title":"Am J Cardiol"},{"key":"R138-1-20210129","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1111\/j.1432-2277.2000.tb02118.x","article-title":"Combined treatment of hypercholesterolaemia of renal transplant allograft recipients with fluvastatin and genfibrozil.","volume":"13","author":"Vergoulas","year":"2000","journal-title":"Transpl Int"},{"key":"R139-1-20210129","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/0272-6386(95)90133-7","article-title":"Effects of nicotinic acid and lovastatin in renal transplant patients: A prospective, randomized, open-labeled crossover trial.","volume":"25","author":"Lal","year":"1995","journal-title":"Am J Kidney Dis"},{"key":"R140-1-20210129","doi-asserted-by":"crossref","first-page":"M704","DOI":"10.1097\/00002480-199507000-00102","article-title":"Does cholestyramine interfere with cyclosporine absorption? A prospective study in renal transplant patients.","volume":"41","author":"Jensen","year":"1995","journal-title":"ASAIO J"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/01.tp.0000262706.28513.6a","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T03:50:44Z","timestamp":1736999444000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007890-200705150-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5,15]]},"references-count":138,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/01.tp.0000262706.28513.6a","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2007,5,15]]}}}